Specifically, “TGF-β response” showed much higher activity in RP11-166D19.1-high PRAD samples than those in RP11-166D19.1-low PRAD samples (P < 2E-16, Figure 3C). Here, TGFB1 is linked to prostate adenocarcinoma.